Answers are grounded in this paper and cite their sources.
Henna-based cosmetic products, particularly those adulterated with para-phenylenediamine (PPD), are an increasingly recognized cause of adverse skin reactions. Despite widespread consumer use, population-level pharmacovigilance data from US regulatory sources remain limited. To characterize the clinical, demographic, and temporal patterns of henna-associated adverse events reported to the US Food and Drug Administration (FDA), and to identify factors associated with case seriousness. Retrospective cross-sectional analysis of henna-related adverse event reports extracted from the FDA Adverse Event Reporting System Cosmetic Public Dashboard, excluding products unrelated to henna (Lawsonia inermis) such as Jagua-based formulations. Statistical analyses included chi-square, Spearman’s rank correlation, and Proportional Reporting Ratio disproportionality analysis. A total of 110 cases were identified (female: 65.5%; pediatric cases <18 years). Black Henna products (classified by product name) represented the largest product category (n = 47, 42.7%). The most frequently reported reactions were pruritus (39.3%), hypersensitivity (32.1%). Serious cases 50.0% of the dataset. No statistically significant association was found between gender and seriousness (χ2=0.133, p = 0.715). hypersensitivity (PRR = 1.54, 95% CI: 0.81–2.92, χ2=1.74, p = 0.187) and urticaria (PRR = 2.26, 95% CI: 0.82–6.18, χ2=2.51, p = 0.113) showed elevated PRR values; however, neither met the predefined signal threshold (PRR ≥ 2.0, χ2≥4.0, n ≥ 3), and no formal disproportionality signal was identified. Henna-associated adverse events affect predominantly young females and pediatric patients. These findings support enhanced regulatory scrutiny under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), mandatory product labeling, and targeted consumer safety communication. What this study addsA comprehensive pharmacovigilance analysis of henna-related ADRs.Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events.Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement. A comprehensive pharmacovigilance analysis of henna-related ADRs. Black henna (PPD-containing) products account for 42% of all cases; 49.1% of all reports are classified as serious events. Clinician should enquire about temporary tattoo exposure in patients with unexplained ACD; PPD patch testing is indicated; consumer safety labeling at body art venues requires regulatory reinforcement.
No takes yet. Share an insight, caveat, or question.
Narasimhaswamy et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: